Every Form 4 that Neurocrine Biosciences Inc (NBIX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NBIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NBIX filings page.
Neurocrine Biosciences Chief Scientific Officer makes charitable stock gift
Neurocrine Biosciences’ Chief Scientific Officer, Jude Onyia, reported a bona fide gift of 3,110 shares of common stock effective February 20, 2026. The filing states this was a gift/charitable contribution, not a market transaction, so no price or proceeds were involved. After the transfer, Onyia directly holds 25,670 shares of Neurocrine Biosciences common stock.
ABERNETHY MATT reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 84,802 shares at a weighted average price of $123.99 per share. Following the reported transactions, holdings were 4,484 shares.
Boyer David W. reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 64,637 shares at a weighted average price of $124.01 per share. Following the reported transactions, holdings were 3,083 shares.
Gano Kyle reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 174,989 shares at a weighted average price of $123.87 per share. Following the reported transactions, holdings were 4,484 shares.
Onyia Jude reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 115,756 shares at a weighted average price of $124.02 per share. Following the reported transactions, holdings were 5,380 shares.
BENEVICH ERIC reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 83,590 shares at a weighted average price of $124.03 per share. Following the reported transactions, holdings were 3,924 shares.
Cooke Julie reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 58,116 shares at a weighted average price of $124.02 per share. Following the reported transactions, holdings were 2,802 shares.
Lippoldt Darin reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 71,708 shares at a weighted average price of $124.00 per share. Following the reported transactions, holdings were 4,036 shares.
Delaet Ingrid reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 78,494 shares at a weighted average price of $124.05 per share. Following the reported transactions, holdings were 2,802 shares.
GORMAN KEVIN CHARLES reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 125,991 shares at a weighted average price of $124.12 per share. Following the reported transactions, holdings were 11,208 shares.
Keswani Sanjay Chandru reported acquisition or exercise transactions in this Form 4 filing.
Neurocrine Biosciences’ Chief Medical Officer receives new equity awards. Sanjay Chandru Keswani was granted a stock option covering 35,827 shares of common stock on February 13, 2026. The option vests monthly, with 1/48 of the shares vesting starting March 13, 2026.
He was also granted 6,285 Restricted Stock Units on the same date. These RSUs vest in four equal annual installments on February 13 of 2027, 2028, 2029, and 2030, with each RSU representing one share of common stock upon settlement.
Neurocrine Biosciences Chief Corp. Affairs Officer David W. Boyer reported routine equity compensation activity. On January 31, 2026, 2,096 restricted stock units converted into the same number of Neurocrine Biosciences common shares at $0 exercise price.
To cover tax withholding on this RSU vesting, the company withheld 1,189 shares of common stock at $136.06 per share, and no shares were sold in the market. Following these transactions, Boyer directly owned 4,713 shares of Neurocrine Biosciences common stock. The underlying RSU grant, originally awarded on January 31, 2022, completed its final vesting tranche of 2,096 shares on the same date.
Neurocrine Biosciences’ Chief Commercial Officer Eric Benevich reported routine equity compensation activity. On January 31, 2026, 2,294 restricted stock units vested and converted into common shares at an exercise price of $0, increasing his direct holdings before tax withholding.
To cover taxes on the vesting, the company withheld 1,292 common shares at $136.06 per share, and no shares were sold in the market. After these transactions, Benevich directly owned 52,755 shares of Neurocrine Biosciences common stock.
Neurocrine Biosciences’ Chief Financial Officer Matt Abernethy reported equity compensation activity involving company stock. On January 31, 2026, 2,437 restricted stock units converted into an equal number of Neurocrine common shares at an exercise price of $0.
To cover tax withholding on this RSU vesting, 1,368 common shares were withheld by Neurocrine at a price of $136.06 per share; no shares were sold on the market. After these transactions, Abernethy directly owned 37,097 common shares, which include 218 shares purchased through the company’s 2018 Employee Stock Purchase Plan.
Neurocrine Biosciences’ Chief Human Resources Officer Julie Cooke reported RSU vesting and tax withholding transactions. On January 31, 2026, 1,741 restricted stock units converted into the same number of common shares at $0 exercise price. To cover taxes, 997 shares of common stock were withheld at $136.06 per share, and no shares were sold on the market.
After these transactions, Cooke beneficially owned 27,602 shares of Neurocrine common stock, including 25,738 shares held by the Cooke Family Trust of 2004, over which she has voting and investment power. Each RSU represents the right to receive one share of common stock.
Neurocrine Biosciences’ Chief Regulatory Officer, Ingrid Delaet, reported routine equity compensation activity. On January 31, 2026, 801 restricted stock units vested and were converted into 801 shares of common stock at an exercise price of $0.
To cover tax withholding on this vesting, 475 shares were withheld by the company at $136.06 per share, as noted in the footnotes, and no shares were sold on the market. After these transactions, Delaet directly owned 5,056 shares of Neurocrine Biosciences common stock.
Neurocrine Biosciences Chief Executive Officer Kyle Gano reported routine equity compensation activity. On January 31, 2026, 2,927 restricted stock units vested and were converted into an equal number of common shares at an exercise price of $0, reflecting previously granted stock awards.
On the same date, 1,580 common shares were withheld by Neurocrine Biosciences at a price of $136.06 per share to cover tax withholding obligations related to this vesting, and the filing states that no shares were sold. Following these transactions, Gano directly owned 141,754 shares of Neurocrine Biosciences common stock.
Neurocrine Biosciences director Kevin Charles Gorman reported routine equity compensation activity. On January 31, 2026, 5,142 restricted stock units converted into the same number of Neurocrine common shares at $0 exercise price. To cover taxes on this vesting, 2,845 shares were withheld by the company at $136.06 per share, and no shares were sold on the market.
After these transactions, Gorman beneficially owned 516,893 common shares, held by the Gorman and Blais Family Trust, over which he has voting and investment power. The vesting completed an RSU grant originally awarded on January 31, 2022.
On January 31, 2026, Neurocrine Biosciences Chief Legal Officer Darin Lippoldt had 2,373 restricted stock units (RSUs) convert into common stock at an exercise price of $0. Each RSU represents the right to receive one share of common stock.
To satisfy tax withholding on this RSU vesting, the company withheld 1,335 shares of common stock at a price of $136.06 per share. The company states that no shares were sold in the market. Following these transactions, Lippoldt directly owned 47,792 shares of Neurocrine Biosciences common stock.
Neurocrine Biosciences Chief Scientific Officer Jude Onyia reported routine equity compensation activity. On January 31, 2026, 238 restricted stock units converted into 238 shares of common stock at an exercise price of $0, increasing Onyia’s direct holdings to 16,119 shares.
On the same date, 142 of those shares were withheld by Neurocrine Biosciences at $136.06 per share to cover tax obligations tied to the RSU vesting, as disclosed in the footnotes. No shares were sold in the open market, and Onyia’s direct ownership after withholding was 15,977 common shares.
Neurocrine Biosciences' Chief Executive Officer Kyle Gano reported option exercises and related stock sales. On January 16, 2026, he exercised non-qualified stock options and incentive stock options to acquire 34,588 and 1,812 shares of common stock, respectively, at an exercise price of $35.99 per share. On the same date, he sold 34,588 shares at a weighted average price of $132.7044 per share and 1,812 shares at a weighted average price of $132.7143 per share under a pre-established Rule 10b5-1 trading plan adopted on May 20, 2025. After these transactions, he directly owned 140,407 shares of Neurocrine Biosciences common stock. The exercised options were granted on February 5, 2016 and were scheduled to expire on February 5, 2026.
Neurocrine Biosciences Chief Commercial Officer filed an amended Form 4 to correct a previously misreported stock option exercise. On November 28, 2025, the insider exercised 12,830 incentive stock options, rather than the 5,970 options originally reported. The options had an exercise price of $35.99 per share and converted into an equal number of common shares. The filing also updates the insider’s reported beneficial ownership of Neurocrine Biosciences common stock and notes that this total includes 204 shares acquired through the company’s 2018 Employee Stock Purchase Plan. The incentive stock option was granted on February 5, 2016, vested in 48 equal monthly installments beginning March 5, 2016, and was scheduled to expire on February 5, 2026.
Neurocrine Biosciences Chief Legal Officer Darin Lippoldt exercised stock options for 3,349 shares of common stock on January 8, 2026. The options had an exercise price of $35.99 per share and were originally granted on February 5, 2016, vesting monthly over four years and scheduled to expire on February 5, 2026.
Following the option exercise, Lippoldt directly held 46,754 shares of Neurocrine Biosciences common stock, and the reported incentive stock option position was reduced to zero.
A director of Neurocrine Biosciences, Inc. reported stock transactions in mid-December 2025. On December 15, 2025, the director exercised 8,276 stock options at $92.35 per share and 1,724 options at $84.95 per share, converting them into common stock. That same day, the director sold 5,000 shares of common stock at a weighted average price of $152.2287 per share, followed by an additional sale of 1,190 shares on December 16, 2025 at a weighted average price of $155.0911 per share. After these trades, the director beneficially owned 6,239 shares of Neurocrine common stock. The filing notes that the sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2025, and that company policy restricts changes to such plans after adoption.
Neurocrine Biosciences reports that Chief Scientific Officer Jude Onyia settled restricted stock units on November 29, 2025, receiving 4,426 shares of common stock. To satisfy tax obligations, 2,248 shares were withheld at $152.16 per share, and no shares were sold. Following these transactions, Onyia directly holds 15,881 common shares.
Neurocrine Biosciences (NBIX) reported an insider equity transaction by a director. On 11/25/2025, the reporting person exercised a non-qualified stock option for 15,000 shares of common stock at an exercise price of $47.89 per share and acquired those shares.
On the same date, the director disposed of 15,000 shares of common stock in an open-market sale coded "S," at a weighted average price of $143.3675 per share, executed under a Rule 10b5-1 trading plan adopted on August 26, 2025. After these transactions, the reporting person directly beneficially owned 7,068 shares of Neurocrine common stock.
Neurocrine Biosciences (NBIX) reported an insider transaction. On 11/05/2025, a director exercised 18,000 non-qualified stock options at an exercise price of $47.89 per share and sold 18,000 common shares at a weighted average price of $151.8161. The sale was executed under a Rule 10b5-1 trading plan adopted on August 6, 2025.
Following these transactions, the reporting person beneficially owned 40,360 shares, held by the Rastetter Family Trust. The option was granted on May 20, 2016 and was due to expire on May 20, 2026.
Neurocrine Biosciences (NBIX) CEO and director reported Form 4 activity. On 11/01/2025, 613 shares of common stock were acquired at $0 upon RSU vesting.
On 11/04/2025, 300 shares were sold at $141.97. The filing states these mandatory sales were made to cover withholding taxes and are intended to meet Rule 10b5-1(c). After these transactions, directly held shares were 140,407, and derivative holdings (RSUs) were 1,842. Beneficial ownership includes 200 shares purchased on 02/28/2025 under the company’s ESPP.